ABETAALPHASYNTAU
"Insight into the synergistic interactions between Aβ amyloid, α-synuclein and Tau"
| Coordinatore | BEN-GURION UNIVERSITY OF THE NEGEV
Organization address
address: Office of the President - Main Campus contact info |
| Nazionalità Coordinatore | Israel [IL] |
| Totale costo | 100˙000 € |
| EC contributo | 100˙000 € |
| Programma | FP7-PEOPLE
Specific programme "People" implementing the Seventh Framework Programme of the European Community for research, technological development and demonstration activities (2007 to 2013) |
| Code Call | FP7-PEOPLE-2011-CIG |
| Funding Scheme | MC-CIG |
| Anno di inizio | 2012 |
| Periodo (anno-mese-giorno) | 2012-03-01 - 2016-02-29 |
Partecipanti
| # | ||||
|---|---|---|---|---|
| 1 |
BEN-GURION UNIVERSITY OF THE NEGEV
Organization address
address: Office of the President - Main Campus contact info |
IL (BEER SHEVA) | coordinator | 100˙000.00 |
Mappa
Word cloud
Esplora la "nuvola delle parole (Word Cloud) per avere un'idea di massima del progetto.
Obiettivo del progetto (Objective)
'Protein aggregation is associated with numerous incurable diseases, including Aβ and tau proteins in Alzheimer’s disease (AD) and α-synuclein in Parkinson’s disease (PD). In vivo studies illustrate that these proteins appear in the brains of both AD and PD patients and that there are synergistic interactions between α-synuclein and tau, Aβ and tau, and α-synuclein and Aβ. Despite the accumulating in vivo evidence of the synergistic interactions between α-synuclein and tau, Aβ and tau, and α-synuclein and Aβ, the mechanism through which the protein pairs aggregate remains controversial. How and which interactions between two types of protein could be involved in protein aggregation is not completely understood. Moreover, it is still not clear which domains in these proteins can interact and what effects result from these interactions. To understand the mechanism of the aggregation between two types of protein, it is necessary to probe and characterize the molecular interactions between oligomers of these proteins. The challenge and the focus of this proposal are to identify the specific interactions between these protein pairs and to probe the oligomeric structures of the proteins at the molecular level. This proposal relies basically on computational tools (molecular modeling and molecular dynamics simulations). The modeling procedure will be based on experiemntal data (ssNMR, cryo-EM) and the constructed oligomeric structures will be validated by collaborative experimental work. The output of this project will be a detailed description of the interactions between proteins that are related to neurodegenerative diseases. Moreover, this proposal may provide insight into the link between AD and PD, and will pave the way to the development of potential drugs to alleviate/prevent the symptoms of neurodegenerative diseases by impending/preventing the interaction between the proteins.'